The Zhitong Finance App learned that China Merchants Securities International released a research report stating that for the first time, Hebo Pharmaceutical (02142.HK) was given an “increase in weight” rating, with a target price of HK$28. The bank estimated the company's valuation of approximately US$3.1 billion, or HK$24.3 billion, through risk-adjusted net present value (RnPV).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.